Live
- PM Modi received with Bihu dance in Laos: Assam CM
- Telangana CM Revanth Reddy Focuses on Increasing Revenue
- Indonesia inaugurates 2 new special economic zones to boost investment
- TCS posts 5 pc net profit growth at Rs 11,909 crore in Q2, hires 5,726 people
- Sensex closes up by 144 points ahead of TCS Q2 results
- Consumer forums cannot adjudicate employer-employee dispute: Delhi HC
- Weapon cache discovered, illegal drugs seized in Afghanistan
- Karnataka govt forms SIT & cabinet sub-committee to probe Covid scam during BJP tenure
- World Mental Health Day: Ancient Indian culture is a guiding light for global mental health issues
- Delhi going into loss for first time: Ilmi on reports of revenue deficit by 2024-25 end
Advanced cancer surgery performed
A team of surgical and medical oncologists led by Dr Srinivas Juluri, Chief of Surgical Oncology (Minimally Invasive Surgery) at American Oncology Institute, performed an advanced Cytoreductive surgery combined with Hyperthermic Intraperitoneal Chemotherapy (CS/HIPEC).
A team of surgical and medical oncologists led by Dr Srinivas Juluri, Chief of Surgical Oncology (Minimally Invasive Surgery) at American Oncology Institute, performed an advanced Cytoreductive surgery combined with Hyperthermic Intraperitoneal Chemotherapy (CS/HIPEC).
This is a complex procedure to treat advanced cancer on the large intestine and was performed on a patient from Kadapa.
Announcing the feat on Wednesday, Dr Juluri said, “HIPEC could be the most effective therapy for select patients and could increase the survival rate manifold.”
“The 47-year-old female patient was suffering from an advanced cancer of the large intestine referred as peritoneal malignancy. After the surgery and HIPEC procedure, she is recovering fast and expected a longer survival than any other therapies available presently,” he added.
Dr Pavan Jadhav and Dr Srinivas Chakravarthy were part of the team that achieved this success. Elaborating on the surgical procedure Dr Juluri said,
“Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CS/HIPEC) is proven to have significant benefit in terms of survival (40-50 per cent), with acceptable morbidity and acceptable mortality for select patients with malignancy in the abdominal area and cases of recurrence.
HIPEC is more effective in terms of treatment as the patient receives a two-way chemo therapy which is more focused and reaches out to the microscopic cells in the affected area.”
“This surgery took us more than 12 hours, and we have cleared the affected areas. The patient is recovering fast and we are expecting a better result than any other conventional therapies,” he said.
Nilesh Gupta, Facility Director at AOI said, “Precision care at American Oncology Institute is delivered by a multi-disciplinary team of experts coupled with effective use of cutting edge technology.
Our doctors are adapting latest advancements of oncology sciences to match the best of the global practices. HIPEC is one such procedure which, we are sure, will open new horizons in cancer treatment.”
Along with the expertise of the doctors and the medical and surgical team, the success of this procedure is also dependent on the hi-tech machine Performer HT, imported from Italy.
